Abstract
In this issue of Blood, Yacoub et al(1) show that pegylated-rIFN-alpha 2a (PEG) is an effective therapy in patients with myeloproliferative neoplasms ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
